A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant mutant form, offering a promising strategy for treating hematological ...

Generally, the current CDK inhibitors in development are more specific and/or more potent. Dinaciclib ... CDK9, CDK10 and CDK11 — is involved in the regulation of cellular transcription ...

“As a highly potent and selective PARP1 inhibitor, it is expected that saruparib could lead to a safer profile that facilitates its combination with chemotherapy or other targeted agents ...

Nimbus utilized its unique structure-based drug discovery engine to identify multiple potent and selective small molecule inhibitors of HPK1. One of these molecules, advanced to in vivo testing ...

today announced that it has successfully discovered a potent, selective, and orally bioavailable small molecule inhibitor of CDK8 for the treatment of cancer using a structure-based generative ...